Deals this week: Idera, Catalyst Biosciences, ADC Therapeutics

27th October 2017 (Last Updated October 27th, 2017 00:00)

Idera Pharmaceuticals, Inc plans to raise $60m through an underwritten public offering of shares of its common stock.

Idera Pharmaceuticals Inc plans to raise $60m through an underwritten public offering of shares of its common stock.

The US-based biopharmaceutical company plans to use the funds to progress the development of its immuno-oncology program and for general corporate purposes.

Catalyst Biosciences Inc and Mosaic Biosciences Inc have signed an agreement to develop the former’s anti-C3 protease assets targeted for the treatment of dry age-related macular degeneration (dAMD) and other retinal disorders.

The companies will co-fund the research with Catalyst Biosciences retaining global commercial rights for the products, while royalties and milestone-based payments will be made to Mosaic Biosciences.

Based in the US, Catalyst Biosciences is a clinical-stage biopharmaceutical company, while Mosaic Biosciences is a biotechnology company also based in the US.

ADC Therapeutics Sarl has raised $200m through the private placement of shares.

"The company plans to use the funds towards ongoing and planned clinical trials."

The Switzerland-based oncology drug discovery and development company plans to use the funds to advance its ADCT-301 and ADCT-402 drug candidates into registrational trials.

Switzerland-based private equity firm HBM Healthcare Investments AG has invested $50m in US-based biopharmaceutical company Y-mAbs Therapeutics Inc.

The investment will enable Y-mAbs Therapeutics to advance the development of its burtomab and naxitamab compounds into regulatory approval.

Danish biotech company Orphazyme ApS plans to raise DKK600m ($94.72m) through an initial public offering of shares.

The company plans to use the funds towards ongoing and planned clinical trials.

US-based biopharmaceutical company scPharmaceuticals, Inc. plans to raise up to $100m through an initial public offering (IPO) of shares of its common stock.

The company plans to use the funds for the commercialisation of Furoscix, and for other general corporate purposes.